Prescribing information

 

   

What really matters when making clinical decisions in psoriasis? Watch the webinar to get an expert view on the value of real-world evidence.

Dr Laura Savage, a consultant dermatologist at Leeds Teaching Hospitals NHS Trust, discusses how clinical decisions are made in practice, the importance of real-world evidence, and what the analysis by Novartis using BADBIR data could mean for the use of Cosentyx in practice.

“…real-world evidence really is the missing piece of this jigsaw where we really want to try to use that to get an understanding of what’s going to happen in the clinical setting.”

– Dr Laura Savage

 

Click here for Cosentyx (secukinumab) prescribing information

Since this webinar, the BADBIR group have published additional data on the relative drug survival of Cosentyx, adalimumab and ustekinumab in 2020.1 Find out more about the latest analysis by the BADBIR group here.

BADBIR, British Association of Dermatologists’ Biologic Interventions Register; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate.

Reference

  1. Yiu ZZN et al. Br J Dermatol 2020; doi:10.1111/bjd.18981.

COS20-C062 July 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]